Expansion of the overseas cell processing contract manufacturing business
First written in FY2024. 2 of 3 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.
0 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「As a market for domestic cell therapy begins to emerge not only in Japan but also across Asia, the company plans to expand its overseas cell processing contract manufacturing business by establishing new cell processing facilities and leveraging the operational expertise it has developed to date.」
The company continues to plan the expansion of its overseas cell processing contract manufacturing business. - FY2025RestatedAnnual report
「As a market for domestic cell therapy begins to emerge not only in Japan but also across Asia, the company plans to expand its overseas cell processing contract manufacturing business by establishing new cell processing facilities and leveraging the operational expertise it has developed to date.」
The company continues to plan the expansion of its overseas cell processing contract manufacturing business. - FY2024First statedAnnual report
「The company plans to expand its overseas cell processing contract manufacturing business by establishing new cell processing facilities and leveraging the operational expertise it has developed to date.」
Against the backdrop of the creation of a cell therapy market in Asia, the company plans to leverage its facilities and operational expertise.